JP7403441B2 - 抗trem2抗体及びその使用方法 - Google Patents
抗trem2抗体及びその使用方法 Download PDFInfo
- Publication number
- JP7403441B2 JP7403441B2 JP2020515175A JP2020515175A JP7403441B2 JP 7403441 B2 JP7403441 B2 JP 7403441B2 JP 2020515175 A JP2020515175 A JP 2020515175A JP 2020515175 A JP2020515175 A JP 2020515175A JP 7403441 B2 JP7403441 B2 JP 7403441B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- trem2
- amino acid
- seq
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023136384A JP2023163183A (ja) | 2017-09-14 | 2023-08-24 | 抗trem2抗体及びその使用方法 |
| JP2025113952A JP2025133893A (ja) | 2017-09-14 | 2025-07-04 | 抗trem2抗体及びその使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558803P | 2017-09-14 | 2017-09-14 | |
| US62/558,803 | 2017-09-14 | ||
| US201762583379P | 2017-11-08 | 2017-11-08 | |
| US62/583,379 | 2017-11-08 | ||
| US201862621380P | 2018-01-24 | 2018-01-24 | |
| US62/621,380 | 2018-01-24 | ||
| PCT/US2018/051166 WO2019055841A1 (en) | 2017-09-14 | 2018-09-14 | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023136384A Division JP2023163183A (ja) | 2017-09-14 | 2023-08-24 | 抗trem2抗体及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020534277A JP2020534277A (ja) | 2020-11-26 |
| JP2020534277A5 JP2020534277A5 (cg-RX-API-DMAC7.html) | 2021-10-14 |
| JP7403441B2 true JP7403441B2 (ja) | 2023-12-22 |
Family
ID=63714159
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020515175A Active JP7403441B2 (ja) | 2017-09-14 | 2018-09-14 | 抗trem2抗体及びその使用方法 |
| JP2023136384A Pending JP2023163183A (ja) | 2017-09-14 | 2023-08-24 | 抗trem2抗体及びその使用方法 |
| JP2025113952A Pending JP2025133893A (ja) | 2017-09-14 | 2025-07-04 | 抗trem2抗体及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023136384A Pending JP2023163183A (ja) | 2017-09-14 | 2023-08-24 | 抗trem2抗体及びその使用方法 |
| JP2025113952A Pending JP2025133893A (ja) | 2017-09-14 | 2025-07-04 | 抗trem2抗体及びその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20200277373A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3681909A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7403441B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111448212A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3075285A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019055841A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201790342A1 (ru) | 2014-08-08 | 2017-07-31 | ЭЛЕКТОР ЭлЭлСи | Антитела к trem2 и способы их применения |
| KR20240056629A (ko) | 2014-09-28 | 2024-04-30 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 자극성 및 비자극성 골수성 세포의 조절 |
| RS63818B1 (sr) | 2017-02-17 | 2023-01-31 | Denali Therapeutics Inc | Konstruisani polipeptidi za vezivanje za receptor transferina |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| HUE062436T2 (hu) | 2017-08-03 | 2023-11-28 | Alector Llc | Anti-trem2 antitestek és alkalmazási módszereik |
| MX2020006213A (es) | 2017-12-12 | 2020-09-14 | Pionyr Immunotherapeutics Inc | Anticuerpos anti-trem2 y metodos relacionados. |
| CA3109763A1 (en) * | 2018-08-16 | 2020-02-20 | Denali Therapeutics Inc. | Engineered bispecific proteins |
| UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| CA3120875A1 (en) | 2018-12-11 | 2020-06-18 | Pionyr Immunotherapeutics, Inc. | Methods of using anti-trem2 antibodies |
| JP7543290B2 (ja) | 2019-02-20 | 2024-09-02 | デナリ セラピューティクス インコーポレイテッド | 抗trem2抗体及びその使用方法 |
| CN110511240B (zh) * | 2019-08-27 | 2022-03-08 | 南京医科大学 | 一种髓细胞触发受体2的内源性配体及其应用 |
| IL293018A (en) * | 2019-11-22 | 2022-07-01 | Lilly Co Eli | trem2 antibodies and their uses |
| CN115003699A (zh) | 2019-12-05 | 2022-09-02 | 艾利妥 | 抗trem2抗体的使用方法 |
| US20230265212A1 (en) * | 2019-12-19 | 2023-08-24 | Kevin S. EISENFRATS | Compositions and methods for oocyte-specific contraception |
| WO2021146256A1 (en) * | 2020-01-13 | 2021-07-22 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| US11124567B2 (en) * | 2020-01-13 | 2021-09-21 | Denali Therapeutics Inc. | Anti-TREM2 antibodies and methods of use thereof |
| CN115768794A (zh) | 2020-02-24 | 2023-03-07 | 艾利妥 | 抗trem2抗体的使用方法 |
| CA3172451A1 (en) | 2020-04-03 | 2021-10-07 | Robert Paul | Methods of use of anti-trem2 antibodies |
| CN111793131A (zh) * | 2020-05-11 | 2020-10-20 | 廊坊天光生物技术有限公司 | 一种用于检测血清中pf4含量的抗体对及其用途 |
| CN116323667A (zh) * | 2020-07-08 | 2023-06-23 | 拉法医疗股份有限公司 | 结合PSMA和γ-δT细胞受体的抗体 |
| CN114075284B (zh) * | 2020-08-17 | 2023-11-17 | 上海元宋生物技术有限公司 | Cd47结合分子及其用途 |
| WO2022045865A1 (ko) * | 2020-08-31 | 2022-03-03 | (주)메디톡스 | 항-vegf 육량체 항체, 및 이를 포함하는 조성물 |
| US20240102094A1 (en) * | 2020-12-03 | 2024-03-28 | Amgen Inc. | Trem2 agonist biomarkers and methods of use thereof |
| CN112526143B (zh) * | 2020-12-03 | 2021-08-03 | 中山大学附属第五医院 | 髓系细胞触发受体2作为新型冠状病毒肺炎诊断或治疗靶点的应用 |
| WO2022241082A1 (en) | 2021-05-14 | 2022-11-17 | Genentech, Inc. | Agonists of trem2 |
| IL308804A (en) * | 2021-05-28 | 2024-01-01 | Vigil Neuroscience Inc | TREM2 agonistic biomarkers and methods of using them |
| CN115505041B (zh) * | 2021-06-22 | 2026-05-05 | 北京免疫方舟医药科技有限公司 | 抗EphA2抗体及其应用 |
| IL285416A (en) * | 2021-08-05 | 2023-03-01 | Yeda Res & Dev | Antibodies for cancer treatment |
| IL311003A (en) | 2021-08-25 | 2024-04-01 | Denali Therapeutics Inc | Anti-2HER antibodies and methods of using them |
| US20240392035A1 (en) * | 2021-08-25 | 2024-11-28 | Denali Therapeutics Inc. | Engineered anti-her2 bispecific proteins |
| WO2023039612A1 (en) * | 2021-09-13 | 2023-03-16 | The Board Of Regents Of The University Of Texas System | Trem2 antigen binding proteins and uses thereof |
| MX2024010324A (es) | 2022-02-23 | 2024-08-30 | Alector Llc | Metodos de uso de anticuerpos anti-trem2. |
| EP4499695A1 (en) | 2022-03-28 | 2025-02-05 | Denali Therapeutics Inc. | Methods for treating brain glucose hypometabolism |
| EP4499693A1 (en) | 2022-03-28 | 2025-02-05 | Denali Therapeutics Inc. | Monovalent anti-trem2 binding molecules and methods of use thereof |
| WO2023215697A1 (en) * | 2022-05-05 | 2023-11-09 | Eli Lilly And Company | Multispecific binding molecules and methods of use thereof |
| JP2025529287A (ja) | 2022-09-06 | 2025-09-04 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | マルファン症候群の処置のためのtrem-2アゴニスト |
| US20240262929A1 (en) * | 2023-02-06 | 2024-08-08 | Ibio, Inc. | Anti-muc16 antibodies |
| WO2024250809A1 (zh) * | 2023-06-08 | 2024-12-12 | 成都优洛生物科技有限公司 | 抗trem2全人源抗体或其抗原结合片段及其应用 |
| AU2024320793A1 (en) | 2023-08-09 | 2026-03-12 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| AU2024323186A1 (en) | 2023-08-09 | 2026-01-15 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| WO2025046298A2 (en) * | 2023-09-01 | 2025-03-06 | iTeos Belgium SA | Anti-trem2 antibodies and methods of use |
| CN117534569B (zh) * | 2023-11-23 | 2026-03-13 | 复旦大学附属华山医院 | S-9-pahsa在制备阿尔兹海默病及认知障碍疾病治疗药物中的用途 |
| CN118546252A (zh) * | 2024-04-02 | 2024-08-27 | 上海宏成药业有限公司 | 抗trem2抗体及其用途 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006503588A (ja) | 2002-08-30 | 2006-02-02 | バイオレクシス ファーマシューティカル コーポレイション | 改変トランスフェリン融合タンパク質 |
| JP2009544301A (ja) | 2006-07-24 | 2009-12-17 | バイオレクシス ファーマシューティカル コーポレーション | エキセンディン融合タンパク質 |
| JP2014030427A (ja) | 2000-09-06 | 2014-02-20 | Aventis Pharma Sa | アミロイドーシスと関連する疾患のための方法及び組成物 |
| WO2017058866A1 (en) | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anti-trem2 antibodies and uses thereof |
| WO2017062672A2 (en) | 2015-10-06 | 2017-04-13 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| JP2017523814A (ja) | 2014-08-08 | 2017-08-24 | アレクトル エルエルシー | 抗trem2抗体及びその使用方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI507525B (zh) * | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| MX367126B (es) * | 2012-08-29 | 2019-08-06 | Hoffmann La Roche | Transporte para atravesar la barrera hematoencefálica. |
-
2018
- 2018-09-14 WO PCT/US2018/051166 patent/WO2019055841A1/en not_active Ceased
- 2018-09-14 US US16/646,536 patent/US20200277373A1/en not_active Abandoned
- 2018-09-14 EP EP18779998.6A patent/EP3681909A1/en active Pending
- 2018-09-14 CN CN201880069782.0A patent/CN111448212A/zh active Pending
- 2018-09-14 CA CA3075285A patent/CA3075285A1/en active Pending
- 2018-09-14 JP JP2020515175A patent/JP7403441B2/ja active Active
-
2023
- 2023-08-24 JP JP2023136384A patent/JP2023163183A/ja active Pending
-
2025
- 2025-07-04 JP JP2025113952A patent/JP2025133893A/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014030427A (ja) | 2000-09-06 | 2014-02-20 | Aventis Pharma Sa | アミロイドーシスと関連する疾患のための方法及び組成物 |
| JP2006503588A (ja) | 2002-08-30 | 2006-02-02 | バイオレクシス ファーマシューティカル コーポレイション | 改変トランスフェリン融合タンパク質 |
| JP2009544301A (ja) | 2006-07-24 | 2009-12-17 | バイオレクシス ファーマシューティカル コーポレーション | エキセンディン融合タンパク質 |
| JP2017523814A (ja) | 2014-08-08 | 2017-08-24 | アレクトル エルエルシー | 抗trem2抗体及びその使用方法 |
| WO2017058866A1 (en) | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anti-trem2 antibodies and uses thereof |
| WO2017062672A2 (en) | 2015-10-06 | 2017-04-13 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
Non-Patent Citations (2)
| Title |
|---|
| Klein C. et al.,Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies,MAbs,Vol. 4(6),2012年,pp. 653-663 |
| Vidarsson G. et al.,IgG subclasses and allotypes: from structure to effector functions,Front Immunol,2014年,Vol. 5:520,pp. 1-17 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025133893A (ja) | 2025-09-11 |
| WO2019055841A1 (en) | 2019-03-21 |
| JP2020534277A (ja) | 2020-11-26 |
| EP3681909A1 (en) | 2020-07-22 |
| US20200277373A1 (en) | 2020-09-03 |
| CA3075285A1 (en) | 2019-03-21 |
| CN111448212A (zh) | 2020-07-24 |
| JP2023163183A (ja) | 2023-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023163183A (ja) | 抗trem2抗体及びその使用方法 | |
| US11124567B2 (en) | Anti-TREM2 antibodies and methods of use thereof | |
| AU2021208482B2 (en) | Anti-TREM2 antibodies and methods of use thereof | |
| US11370832B2 (en) | Anti-Tau antibodies and methods of use thereof | |
| KR102695287B1 (ko) | 항-phf-타우 항체 및 이의 용도 | |
| US20220119522A1 (en) | Anti-trem2 antibodies and methods of use thereof | |
| US11155627B2 (en) | Anti-c-Met/anti-Ang2 bispecific antibody | |
| US9808507B2 (en) | Anti-c-Met/anti-Ang2 bispecific antibody | |
| US20140302039A1 (en) | Combination therapy using anti-c-met antibody and anti-ang-2 antibody | |
| JP2021529796A (ja) | 多特異性Wnt代替分子及びその使用 | |
| TW201827466A (zh) | 抗-tau抗體及使用方法 | |
| JP7667075B2 (ja) | アンタゴニスト | |
| JP2024009870A (ja) | 抗phf-タウ抗体及びその使用 | |
| WO2018237338A1 (en) | Anti-alpha-synuclein antibodies and methods of use thereof | |
| KR20180021875A (ko) | 다중특이적 결합 단백질 | |
| KR20230034367A (ko) | 항-종양 괴사 인자 수용체 (tnfr2) 항체 및 그 용도 | |
| KR102106160B1 (ko) | 항 Ang2 항체 | |
| KR20220092859A (ko) | 항-cxcr2 항체 및 이의 용도 | |
| CN121057749A (zh) | 抗cd3多特异性抗体和使用方法 | |
| EA046752B1 (ru) | Полипептиды, препятствующие передаче wnt сигналов в опухолевых клетках |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20210125 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210906 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210906 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220729 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220801 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221026 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230116 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230427 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230824 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230825 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230914 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231109 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231208 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231212 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7403441 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |